Mode
Text Size
Log in / Sign up
N/A Completed N=124 Treatment

Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes

Source: ClinicalTrials.gov NCT02463097 ↗
Enrolled (actual)
124
Serious AEs
1.6%
Results posted
Apr 2017
Primary outcomePrimary: Change in A1C — -0.5 Percent

Summary

This study is a single-arm, multi-center, Home and Hotel Clinical Investigation in subjects with type 1 diabetes on insulin pump therapy. The purpose of this study is to demonstrate that the closed loop algorithm that is built into the 670G insulin pump is safe as part of the overall system.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in A1C
-0.5 —
SECONDARY
Number of Severe Hypoglycemia Events
— —
SECONDARY
Number of Diabetic Ketoacidosis (DKA) Events
— —

Eligibility Criteria

Inclusion Criteria

  • Is age 14 - 75 years at time of screening
  • Has a clinical diagnosis of type 1 diabetes for 2 years or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis
  • Is willing to participate in a hotel study for the specified duration of hotel stay.
  • Must have companion who will sleep in the same dwelling place every night during the study period and should also be able to call the subject daily in the event the subject is traveling.
  • Is willing to perform ≥ 4 finger stick blood glucose measurements daily
  • Is willing to perform required sensor calibrations
  • Is willing to wear the system continuously throughout the study
  • Has a Glycosylated hemoglobin (A1C) value less than 10.0% (as processed by Central Lab) at time of screening visit
  • Has TSH in the normal range OR if the TSH is out of normal reference range the Free T3 is below or within the lab's reference range and Free T4 is within the normal reference range.
  • Pump therapy for greater than 6 months prior to screening (with or without CGM experience)
  • Is willing to upload data from the study pump, must have Internet access and a computer system that meets the requirements for uploading the study pump
  • If subject has celiac disease, it has been adequately treated as determined by the investigator
  • Is willing to take one of the following insulins and can financially support the use of either of the 2 insulin preparations throughout the course of the study (i.e. co-payments for insulin with insurance or able to pay full amount)
  • Humalog® (insulin lispro injection)
  • NovoLog® (insulin aspart)
  • With history of cardiovascular event 1 year or more from the time of screening must have an EKG within 6 months prior to screening or during screening. If subject has an abnormal EKG, participation is allowed if there is clearance from a cardiologist
  • With 3 or more cardiovascular risk factors listed below must have an EKG within 6 months prior to screening or during screening. If subject has an abnormal EKG, participation is allowed if there is clearance from a cardiologist

Cardiovascular risk factors include:

  • Age >35 years
  • Type 1 diabetes of >15 years' duration
  • Presence of any additional risk factor for coronary artery disease
  • Presence of microvascular disease (proliferative retinopathy or nephropathy, including microalbuminuria)
  • Presence of peripheral vascular disease
  • Presence of autonomic neuropathy
  • With history of cardiovascular event 1 year or more from the time of screening must have a stress test within 6 months prior to screening or during run in period. If subject fails stress test, participation is allowed if there is clearance from a cardiologist
  • Must be able to speak and be literate in English

Exclusion Criteria

  • Has a history of 2 or more episodes of severe hypoglycemia, which resulted in any the following during the 6 months prior to screening:
  • Medical assistance (i.e. Paramedics, Emergency Room ( ER) or Hospitalization)
  • Coma
  • Seizures
  • Is unable to tolerate tape adhesive in the area of sensor placement
  • Has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection)
  • Females who are sexually active and able to conceive will be excluded if they are not using an effective method of contraception and do not agree to continue using an effective method of contraception for the duration of the study as determined by investigator.
  • Has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease
  • Is being treated for hyperthyroidism at time of screening
  • Has diagnosis of adrenal insuffic
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02463097). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search